West Pharmaceutical Services (WST)
Health Care · pharmaceutical packaging and delivery systems · NYSE
West Pharmaceutical Services provides essential high-quality, sterile packaging and delivery systems for injectable medications globally.
What West Pharmaceutical Services does
West Pharmaceutical Services designs and manufactures injectable pharmaceutical packaging and delivery systems. Its products, including stoppers, seals, syringes, and auto-injectors, are essential for the safe and effective containment and delivery of injectable drugs and vaccines. The company serves the global pharmaceutical, biotechnology, and generic drug industries.
Themes: pharmaceutical containment and delivery, injectable drug infrastructure, vaccine and biologic supply chain, drug delivery innovation
Fundamentals
- Price$353.08 as of 2026-08-21 close
- Market cap$24.8B as of 2026-08-21
- 1-year return+45.5% 2025-08-21 close $242.63 → 2026-08-21 close $353.08
- P/E43.89 as of 2026-08-24
- Net margin+17.0% as of 2026-08-24
- Gross margin+36.8% as of 2026-08-24
- ROE+18.5% as of 2026-08-24
- Debt / equity0.07 as of 2026-08-24
- Revenue growth (YoY)+12.4% as of 2026-08-24
- Revenue CAGR (3y)+2.1% SEC XBRL
- Beta1.13 as of 2026-08-24
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.3%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How WST compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
WST is in the Health Care Long-term Top 10.
Health Care Long-term Top 10 — since 18 Aug 2026
Long-term score
57.8 #239 of 987 scored · #11 of 57 in Health Care
Financial health 73rd (debt to equity 0.1, free cash flow margin 13.1%) and long-term trend 71st (trading above its 200-day average); weakest is valuation (17th, price to earnings 45.1, price to book 8.3).
Short-term score
49.1 #855 of 1,704 scored · #152 of 240 in Health Care
Momentum 60th: its RSI momentum gauge is in neutral territory; trend 58th: the price is 2% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 37th: no fresh 20-day breakout up or down.
In this list since 18 Aug 2026 — currently 10th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 10, score 56.2.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, WST's dividend was covered by reported results (earnings payout 12%, free-cash-flow payout 13%). This describes past coverage, not a forecast.
- Earnings payout12% dividends / net income
- Free-cash-flow payout13% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How West Pharmaceutical Services looks technically
West Pharmaceutical Services (WST) is trading 22.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 73 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 21 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 22.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $347.57 | $347.57 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $289.41 | $289.41 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 358.67. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 73 trading days ago — a "golden cross", a bullish long-term signal | 73 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($343.02 to $360.25) — its "stochastic" reading is 58 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 58.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $382.40 | $382.40 |
|---|---|---|
| From the 52-week high | it is 7.7% below its 52-week high (its highest price of the past year) | -7.7% |
| Above the 52-week low | it is 57.7% above its 52-week low (its lowest price of the past year) | +57.7% |
| Below the 52-week high | it is 7.7% below its highest point of the past year | 7.7% |
| Since a 20-day breakout | it made a new 20-day low about 21 trading days ago | 21 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $475.35 (set on 2021-09-09) | $475.35 |
| Given back of the 52-week move | over the past year its closes ranged ($230.95 to $365.74), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $278.13 to $282.44. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.4% |
| From the all-time high | it is 25.7% below its all-time high | -25.7% |
| Nearest price level | it is trading 1.3% above a support level at $348.34 — a price it turned at five times since 2024-10-24, most recently on 2026-08-14. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $9.29 (set on 2005-10-20) | $9.29 |
| Above the all-time low | it is 3700.6% above its all-time low | +3,701% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 4% of the past ~6 months), which often precedes a bigger move | 4th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.23 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.23 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $334.40 and $359.69 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $334.40 – $347.04 – $359.69 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 7.7 daily ranges above its 200-day average price (22.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.78× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 48 sessions ago and has not traded back through the level it left behind at 319.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.0 percentage points (the stock lost 1.7% while the market gained 2.3%) | -4.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.6 percentage points (the stock gained 11.7% while the market gained 3.1%) | +8.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 35.4 percentage points (the stock gained 46.4% while the market gained 11.1%) | +35.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 25.0 percentage points (the stock gained 45.5% while the market gained 20.5%) | +25.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.5% of the share price. | +1.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $288.63 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +22.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-07-23 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $344.55 — a volume-weighted average of daily closes over 22 sessions, not a true tick-by-tick VWAP. | +2.5% |
Price levels it has turned at before
WST last closed at $353.08 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $348.34 | Support | 1.3% below the last close | turned there five times · 2024-10-24 to 2026-08-14 |
| $328.47 | Support | 7.0% below the last close | turned there twice · 2024-11-29 to 2026-05-11 |
| $321.65 | Support | 8.9% below the last close | turned there 8 times · 2024-08-30 to 2026-07-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $358.67.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$404.73 range $340.00 – $459.00; median $410.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for WST
- Consensus EPS estimate$2.19 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the biopharmaceutical and pharmaceutical industry.","Risks associated with international operations and supply chain management.","Complexity and regulatory requirements related to manufacturing standards."]
What changed in the latest 10-Q
AI-assisted comparison of WST's 10-Q filed 2026-04-23 against the prior one filed 2025-10-23.
Management's Discussion & Analysis (MD&A)
- Added:
- New macroeconomic disclosure added in 2026 filing: U.S. government imposed additional tariffs beginning in 2025 (filed 2026-04-23)
- New disclosure in 2026 filing regarding Middle East conflict impact on petro-chemical costs and inflationary pressures (filed 2026-04-23)
- New disclosure in 2026 filing stating Israel-based facilities continued to operate normally in Q1 2026 with no business disruption (filed 2026-04-23)
- New financial reconciliation table added for three months ended March 31, 2026 with U.S. GAAP and non-U.S. GAAP measures (filed 2026-04-23)
- New financial reconciliation table added for three months ended March 31, 2025 for year-over-year comparison (filed 2026-04-23)
- New line item added: SmartDose® 3.5mL sale unallocated item in Q1 2026 reconciliation with $1.9M operating profit adjustment (filed 2026-04-23)
- New detailed footnote disclosure added regarding Q1 2026 restructuring charges including $12.0M one-time tax cost from internal legal entity restructuring (filed 2026-04-23)
- Removed:
- Removed reference to '2024 Annual Report' in favor of '2025 Annual Report' (filed 2026-04-23)
- Removed nine-month financial data for periods ended September 30, 2025 and 2024 (filed 2026-04-23)
- Removed detailed Israel conflict description stating facilities 'substantially operate' prior to conflict and monitoring impact on suppliers (filed 2026-04-23)
- Removed disclosure regarding stock-based compensation tax benefits for nine months ended September 30, 2025 and 2024 (filed 2026-04-23)
- Removed segment name 'Contract-Manufactured Products' in favor of 'West Vantage™' effective Q1 2026 (filed 2026-04-23)
- Reworded:
- Tariff language changed from 'In recent months, the U.S. government has imposed' to 'Beginning in 2025, the U.S. government imposed' (filed 2026-04-23)
- Materiality assessment changed from tariff impact to '2025 results' to '2026 results' (filed 2026-04-23)
- Middle East conflict discussion expanded from Israel-specific focus to broader regional impact on petro-chemical costs and inflation (filed 2026-04-23)
- Segment description: Contract-Manufactured Products changed to West Vantage with note that name does not affect composition or reported financials (filed 2026-04-23)
- Contract-Manufactured Products description expanded to include 'combination product assembly and packaging' services (filed 2026-04-23)
- Non-U.S. GAAP disclosure: 'specifically-identified' changed to 'specifically identified' (minor hyphenation change, filed 2026-04-23)
- Notes:
- Newer filing covers Q1 2026 (three months ended March 31, 2026) while older filing covers Q3 2025 (three months ended September 30, 2025), making direct period comparison inherently different
- The text of the older filing appears truncated at the end, potentially affecting completeness of comparison
- Segment rename from 'Contract-Manufactured Products' to 'West Vantage™' is presented as effective Q1 2026 with statement that it does not affect prior reported figures
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 2 sells ($1M) — 2 selling insiders
Most recent open-market transaction: 2026-04-27. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about WST's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for WST from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding WST as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 12,395,896
- Reported value $3,106,907,539
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 7 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
WST had 2,510,898 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
WST had 3.57% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.54 days to cover at the same settlement.
- Reported short interest (shares) 2,510,898
- Short interest (% of shares outstanding) 3.57%
- Prior settlement (shares) 2,360,270
- Reported change 6.38%
- Days to cover (reported) 2.54
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Becton, Dickinson and Company (BDX)
- Gerresheimer AG (GXI.DE)
- Schott Pharma (1SXP.DE)
- Stevanato Group (STVN)
- Terumo Corporation (TRMUY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare WST vs…
West Pharmaceutical Services is found in…
Frequently asked questions
What does West Pharmaceutical Services (WST) do?
West Pharmaceutical Services designs and manufactures injectable pharmaceutical packaging and delivery systems. Its products, including stoppers, seals, syringes, and auto-injectors, are essential for the safe and effective containment and delivery of injectable drugs and vaccines. The company serves the global pharmaceutical, biotechnology, and generic drug industries.
What sector is West Pharmaceutical Services (WST) in?
West Pharmaceutical Services (WST) is classified in the Health Care sector. Its industry is pharmaceutical packaging and delivery systems. It trades on NYSE.
Does WST pay a dividend?
Yes — West Pharmaceutical Services (WST) pays a dividend, with an indicated yield of about 0.33% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are West Pharmaceutical Services's (WST) competitors?
Notable peers of West Pharmaceutical Services (WST) include Becton, Dickinson and Company, Gerresheimer AG, Schott Pharma (1SXP.DE), Stevanato Group and Terumo Corporation. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in WST?
Yes — we hold 5 matched STOCK Act disclosures for WST from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is West Pharmaceutical Services (WST) overbought or oversold right now?
West Pharmaceutical Services (WST) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on WST come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.